Weleader Biomedical Co (ROCO:7713) Other Financing: NT$-153 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
47 GF Score
Price NT$70.60
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Other Financing?

Weleader Biomedical Co ROCO:7713 -0.14% 47 Other Financing is NT$-153 Mil as of Dec. 2025. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review.

Weleader Biomedical Co's Other Financing for the three months ended in Dec. 2025 was NT$0 Mil.

Weleader Biomedical Co's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-153 Mil.

Weleader Biomedical Co Other Financing Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Other Financing Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 -0.02 0.00 0.00 0.02

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -153.17 0.00 0.02
ROCO:7713
47GF Score
Weleader Biomedical Co Ltd ROCO:7713
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-153 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$-153 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Other Financing of NT$-153 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Other Financing too high?
Weleader Biomedical Co's current Other Financing is NT$-153 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Other Financing compare to ABT and SYK?
Weleader Biomedical Co's Other Financing of NT$-153 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Other Financing is NT$-153 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Other Financing of NT$-153 Mil. The current Other Financing is NT$-153 Mil. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Other Financing is NT$-153 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score

Get the complete analysis for ROCO:7713

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.60
Price